Psychedelic medicine took a major step forward this month as JAMA published results from the first randomized, placebo-controlled trial of LSD for anxiety.
A new article published in Nature by Dr.
AbbVie Inc.
By Jody Chu and James Bunn.
After a ten-month pause, Psychedelic Health returns — renewed in purpose and ready to stand with an industry that has faced some of its most challenging...
In recent years, the UK has seen a resurgence in interest and investment in psychedelic research, particularly focusing on substances like psilocybin and MDMA.
The past year featured some of Britain’s most significant landmarks in advancing access to psychedelic medicine.
A newly published academic review has revisited one of the most sensational — and disputed — theories in psychedelic history: that early Christianity emerged from fertility...
A trend towards the legalization of psychedelic substances for medical use continues across the English-speaking world.
For the first time, a government-funded UK trial will investigate psilocybin-assisted psychotherapy for targetting relapses associated with opioid addiction, aiming to bring an innovative new therapy...
The European Citizens’ Initiative for Psychedelic-Assisted Therapies – launching at the start of 2025 – is aiming to collect one million signatures to urge the European...
A six-month follow-up study of a Phase 2 clinical trial investigating psilocybin versus escitalopram for the treatment of major depressive disorder has shown positive results.
